Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

Status:
Completed

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

The purpose of this study was to assess the safety of repeat doses of serelaxin in chronic heart failure.

Phase 2

Novartis Pharmaceuticals